Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, due to personal funding needs [1][4]. Group 1: Shareholder Information - Shuai Fangwen currently holds 853,574,906 shares, which is 41.38% of the total share capital [1]. - The planned reduction will occur within three months from October 29, 2025, to January 28, 2026, through centralized bidding or block trading [1]. - After the reduction, Shuai Fangwen will remain the controlling shareholder, and the company's control will not change [4]. Group 2: Financial Implications - Based on the closing price of 3.49 yuan on September 29, 2023, the planned cash-out from this reduction is approximately 147 million yuan [2]. - Since 2017, Shuai Fangwen has cumulatively reduced his holdings by 88,769,100 shares, amounting to approximately 1.05 billion yuan in cash [5]. - Including the current planned reduction, the total cash-out from share reductions will reach approximately 1.197 billion yuan [5].

Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

Core Viewpoint - Several companies are planning to reduce their shareholdings, indicating potential shifts in ownership and investor sentiment in the market [1] Shareholder Reductions - Senba Sensor's actual controller's concerted action party plans to reduce holdings by no more than 1.09% [1] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [1] - Andeli's shareholder BVI Donghua plans to reduce holdings by no more than 1.00% [1] - Zhiyang Innovation's controlling shareholder and its concerted action party plan to reduce a total of no more than 4.225 million shares [1] - Sichuan Gold's shareholder Beijing Jinyang intends to reduce holdings by no more than 1.8% [1] - Guoji Heavy Industry's shareholders, including Bank of China Deyang Branch and Bank of China Zhenjiang Runzhou Branch, plan to reduce a total of no more than 1% [1] - Meixin Sheng's shareholder WI Harper Fund VII plans to reduce holdings by no more than 1% [1] - Yanmian Technology's actual controller and controlling shareholder Liu Yan plan to reduce a total of 1.2897% of the company's shares [1] - Jingwei Henghai's supervisor Cui Wenge plans to reduce no more than 600,000 shares [1] - New Xiangwei's shareholder Kehongxin plans to reduce holdings by no more than 1% [1] - Wujin Stainless Steel's three executives plan to reduce a total of no more than 623,400 shares [1] - Zhongrun Optical's director Lu Gaofei plans to reduce no more than 695,300 shares [1] Regulatory Actions - *ST Mubang's actual controller Liao Zhiyuan has received a notice of investigation from the China Securities Regulatory Commission [1] - Youkeshu's shareholder has also received a notice of investigation from the China Securities Regulatory Commission [1]

Mergers and Acquisitions - DiAo Micro plans to acquire equity in Rongpai Semiconductor through a combination of issuing shares and cash payment, with the stock suspended for up to 10 trading days [1] - Jingye Intelligent intends to purchase 51% of Hefei Shengwen for 108 million yuan, aiming to enhance its strategic presence in the military sector [2] - Guolin Technology is planning a cash acquisition of 91.07% of Xinjiang Kailianjie, which specializes in the production of maleic anhydride, potentially creating a synergistic relationship with its existing business [3] Shareholding Changes - Erkang Pharmaceutical's controlling shareholder plans to reduce holdings by up to 42 million shares, representing 2.04% of the total share capital [4] - Senba Sensor's actual controller's associated party intends to reduce holdings by no more than 308.69 thousand shares, accounting for 1.09% of the total share capital [5] - Zhiyang Innovation's controlling shareholder and associated parties plan to reduce holdings by up to 422.5 thousand shares, which is 1.82% of the total share capital, during a specified period [6] Regulatory Issues - Youkeshu announced that three shareholders are under investigation by the China Securities Regulatory Commission for failing to disclose significant information [7] - *ST Xingnong received a notice from the China Securities Regulatory Commission regarding an investigation for suspected information disclosure violations, while its operations remain normal [8] - *ST Mubang's actual controller is also under investigation by the China Securities Regulatory Commission for failing to disclose non-operational fund transactions [10]

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, within a three-month period starting from October 29, 2025 [1] Summary by Category - **Shareholder Actions** - Shuai Fangwen intends to reduce his holdings through centralized bidding or block trading methods [1] - The reduction period is set from October 29, 2025, to January 28, 2026 [1]

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Shuai Fangwen, plans to reduce his stake in the company by up to 42 million shares, representing 2.04% of the total share capital, within a three-month period starting from October 29, 2025, to January 28, 2026 [1] Summary by Relevant Categories Shareholder Actions - Shuai Fangwen intends to reduce his holdings through centralized bidding or block trading methods [1] Share Capital Impact - The planned reduction amounts to a maximum of 42 million shares, which is equivalent to 2.04% of the company's total share capital [1]

Core Viewpoint - The controlling shareholder of Erkang Pharmaceutical, Mr. Shuai Fangwen, plans to reduce his shareholding by up to 42 million shares, representing 2.04% of the company's total equity, within a specified timeframe [1] Shareholding Details - Mr. Shuai Fangwen currently holds 853,574,906 shares, which accounts for 41.38% of the total share capital of the company [1] - The planned reduction will take place from October 29, 2025, to January 28, 2026, through centralized bidding or block trading [1]

Group 1 - The core point of the news is that Hunan Erkang Pharmaceutical Co., Ltd. announced a pre-disclosure regarding the reduction of shares by its controlling shareholder, Shuai Fangwen, due to personal funding needs [1][2]. Group 2 - Shuai Fangwen holds 853,574,906 shares, accounting for 41.38% of the company's total share capital [2]. - The reduction plan details include a maximum reduction of 42,000,000 shares, which represents 2.04% of the total share capital, within a specified period from October 29, 2025, to January 28, 2026 [2]. - The reduction will be executed through centralized bidding and block trading, with limits on the total number of shares that can be sold in a 90-day period [2].

人民财讯9月29日电，尔康制药（300267）9月29日公告，持股41.38%的公司控股股东帅放文，计划在 15个交易日后的3个月内，以集中竞价或大宗交易方式合计减持公司股份不超过4200万股，即不超过公 司总股本的2.04%。 ...

证券代码：300267 证券简称：尔康制药 公告编号：2025-027 湖南尔康制药股份有限公司 关于控股股东减持公司股份的预披露公告 控股股东帅放文先生保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 公司控股股东帅放文先生持有公司股份 853,574,906 股，占本公司总股本的 41.38%，计划在本公告发布之日起 15 个交易日后的 3 个月内（即 2025 年 10 月 29 日至 2026 年 1 月 28 日）以集中竞价或大宗交易方式合计减持公司股份不超 过 42,000,000 股，即不超过本公司总股本的 2.04%。以上股东在任意连续九十个 自然日内通过证券交易所集中竞价交易减持股份的总数，不超过公司股份总数的 1%；在任意连续九十个自然日内，通过大宗交易方式减持股份的总数，不超过 公司股份总数的 2%。 湖南尔康制药股份有限公司（以下简称"公司"）于近日收到控股股东帅放 文先生出具的《股份变动计划告知函》，现将有关事项公告如下： 一、计划减持股东的基本情况 公司控股股东帅放文 ...